Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8892437 | 0.99 | SIRT2 (0.46) | SIRT2FFAR1KEAP1CYP11B1CYP11B2 | |
| SCHEMBL9263718 | 0.92 | SIRT2 (0.45) | SIRT2 | |
| SCHEMBL27351346 | 0.91 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL7705897 | 0.90 | SIRT2 (0.44) | SIRT2 | |
| SCHEMBL27451583 | 0.90 | SIRT2 (0.46) | SIRT2FFAR1CYP11B1CYP11B2NMBR | |
| SCHEMBL25389429 | 0.89 | MAPT (0.45) | SIRT2 | |
| SCHEMBL25310574 | 0.89 | MAPT (0.45) | SIRT2 | |
| SCHEMBL25390529 | 0.89 | MAPT (0.45) | SIRT2 | |
| SCHEMBL25389258 | 0.89 | MAPT (0.45) | SIRT2 | |
| SCHEMBL9234830 | 0.89 | SIRT2 (0.45) | SIRT2FFAR1CYP11B1CYP11B2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2026-05-07 | — | — | US | disclosed |
| CN-118772227-A | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-10-15 | — | — | CN | disclosed |
| CN-110799520-B | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11530298-B2 | Poly(phosphoesters) for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530298-B2 | Poly(phosphoesters) for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4047039-A1 | POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS | Translate Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-108884058-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-5565476-A | RENIN INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND HYPERTENSION | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5554634-A | HYPOTENSIVE | BIO-MEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-09-10 | — | — | US | disclosed |
| US-5541163-A | HYPOTENSIVE AGENTS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-07-30 | — | — | US | disclosed |
| US-5523315-A | N-(hydroxyethyl)butanediamide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-06-04 | — | — | US | disclosed |
| EP-0675112-A1 | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994007845-A1 | N-(HYDROXYETHYL)BUTANEDIAMIDE DERIVATIVES AS RENIN INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994007846-A1 | RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | disclosed |
| EP-0589445-A1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
| EP-0589446-A1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530298-B2 | Poly(phosphoesters) for delivery of nucleic acids | POLR2E, POLR2H, POLR1A | SIRT2 3570/4885FFAR1 2464/4885KEAP1 4491/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | SIRT2 1289/4885FFAR1 92/4885KEAP1 2289/4885 |
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | GLP1R, GIPR, ARRB1 | SIRT2 3156/4885FFAR1 191/4885KEAP1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.